Brain Cancer Clinical Trials in Phoenix

Showing 61-80 of 133 trials

Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma

NCT01774253

The purpose of this research study is to evaluate an investigational drug (Vismodegib) for Pontine Glioma that is growing or has come back (reoccurred). This study will look at the tumors response to the study drug, Vismodegib, and will also look at the safety and tolerability of Vismodegib. Vismodegib has been tested in multiple adult clinical trials and one pediatric trial. Laboratory testing in pontine gliomas suggests that this drug may be effective in treating this disease.

Pontine Glioma

Giselle Sholler9 participantsStarted May 2013

Phoenix, Arizona, United States • Grand Rapids, Michigan, United States

COMPLETEDPhase 3< 1 mile

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02617589

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-unmethylated (the MGMT gene is not altered by a chemical change). Patients will receive Nivolumab every two weeks in addition to radiation therapy, and then every four weeks. They will be compared to patients receiving standard therapy with temozolomide in addition to radiation therapy.

Brain Cancer

Bristol-Myers Squibb560 participantsStarted Mar 2016

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +122 more locations

Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Brain Cancer Trials in Other Cities

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Expanded Access Protocol Using 131I-MIBG

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Other Conditions in Phoenix